Literature DB >> 22352893

CD33-related siglecs as potential modulators of inflammatory responses.

Paul R Crocker1, Sarah J McMillan, Hannah E Richards.   

Abstract

The immune system must be tightly regulated to prevent unwanted tissue damage caused by exaggerated immune and inflammatory reactions. Inhibitory and activating immune receptors play a crucial role in this function via phosphotyrosine-dependent signaling pathways. A significant body of evidence has accumulated suggesting that the siglec family of sialic acid binding Ig-like lectins makes an important contribution to this immunoregulation. The CD33-related siglecs are a distinct subset of inhibitory and activating receptors, expressed primarily on leukocytes in a cell type-specific manner. Here, we critically assess the in vitro and in vivo evidence on the functional role for CD33-related siglecs in modulation of inflammatory and immune responses.
© 2012 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22352893     DOI: 10.1111/j.1749-6632.2011.06449.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  43 in total

1.  Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.

Authors:  Ana Griciuc; Alberto Serrano-Pozo; Antonio R Parrado; Andrea N Lesinski; Caroline N Asselin; Kristina Mullin; Basavaraj Hooli; Se Hoon Choi; Bradley T Hyman; Rudolph E Tanzi
Journal:  Neuron       Date:  2013-04-25       Impact factor: 17.173

2.  Enhanced lentiviral vector production in 293FT cells expressing Siglec-9.

Authors:  Toru Shoji; Hiroshi Higuchi; Yoshinori Zaitsu; Ken-Ichi Nishijima; Shinji Iijima
Journal:  Cytotechnology       Date:  2014-01-25       Impact factor: 2.058

3.  Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.

Authors:  Michal A Stanczak; Shoib S Siddiqui; Marcel P Trefny; Daniela S Thommen; Kayluz Frias Boligan; Stephan von Gunten; Alexandar Tzankov; Lothar Tietze; Didier Lardinois; Viola Heinzelmann-Schwarz; Michael von Bergwelt-Baildon; Wu Zhang; Heinz-Josef Lenz; Younghun Han; Christopher I Amos; Mohammedyaseen Syedbasha; Adrian Egli; Frank Stenner; Daniel E Speiser; Ajit Varki; Alfred Zippelius; Heinz Läubli
Journal:  J Clin Invest       Date:  2018-09-24       Impact factor: 14.808

4.  Lectin-dependent localization of cell surface sialic acid-binding lectin Siglec-9.

Authors:  Munetoshi Ando; Toru Shoji; Wenjie Tu; Hiroshi Higuchi; Ken-Ichi Nishijima; Shinji Iijima
Journal:  Cytotechnology       Date:  2014-01-22       Impact factor: 2.058

Review 5.  Microglial dysfunction in brain aging and Alzheimer's disease.

Authors:  Kira Irving Mosher; Tony Wyss-Coray
Journal:  Biochem Pharmacol       Date:  2014-01-18       Impact factor: 5.858

6.  Effects of Siglec on the expression of IL-10 in the macrophage cell line RAW264.

Authors:  Toru Shoji; Hiroshi Higuchi; Ken-Ichi Nishijima; Shinji Iijima
Journal:  Cytotechnology       Date:  2014-04-09       Impact factor: 2.058

7.  Association of CD33 polymorphism rs3865444 with Alzheimer's disease pathology and CD33 expression in human cerebral cortex.

Authors:  Douglas G Walker; Alexis M Whetzel; Geidy Serrano; Lucia I Sue; Thomas G Beach; Lih-Fen Lue
Journal:  Neurobiol Aging       Date:  2014-10-02       Impact factor: 4.673

Review 8.  Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Authors:  Kayluz Frias Boligan; Circe Mesa; Luis Enrique Fernandez; Stephan von Gunten
Journal:  Cell Mol Life Sci       Date:  2014-12-07       Impact factor: 9.261

Review 9.  The regulatory power of glycans and their binding partners in immunity.

Authors:  Jenny L Johnson; Mark B Jones; Sean O Ryan; Brian A Cobb
Journal:  Trends Immunol       Date:  2013-02-26       Impact factor: 16.687

Review 10.  The involvement of microglia in Alzheimer's disease: a new dog in the fight.

Authors:  Zachery Moore; Juliet M Taylor; Peter J Crack
Journal:  Br J Pharmacol       Date:  2018-12-18       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.